Press release
Dementia with Diabetes Market to Reach USD 15.2 Billion by 2034
Dementia with Diabetes
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71933
This dual diagnosis poses complex management challenges, as patients often require multimodal therapy addressing both metabolic and cognitive decline. The market is expanding due to aging populations, rising diabetes prevalence, and integration of neurocognitive screening in diabetes care.
Market Overview
• Market Size (2024): USD 8.4 billion
• Forecast (2034): USD 15.2 billion
• CAGR (2025-2034): 6.2%
Growth is fueled by aging demographics, increasing dementia diagnosis in diabetic populations, and therapeutic advances targeting metabolic-cognitive interactions.
Key Highlights:
• People with type 2 diabetes have a 50-100% higher risk of dementia compared to non-diabetics.
• Alzheimer's disease is sometimes referred to as "type 3 diabetes" due to its metabolic links.
• Current management combines antidiabetics, cognitive enhancers, and lifestyle modifications.
• Emerging therapies focus on insulin sensitizers, GLP-1 receptor agonists, and neuroprotective drugs.
Segmentation Analysis
By Product Type:
• Pharmacological Therapies
o Antidiabetics (Metformin, GLP-1 receptor agonists, SGLT2 inhibitors, Insulin)
o Cognitive Enhancers (Donepezil, Rivastigmine, Memantine)
o Combination Approaches (antidiabetics with neuroprotective effects - e.g., GLP-1 therapies)
o Pipeline Agents (neuroinflammation modulators, metabolic-cognitive drugs)
• Non-Pharmacological Interventions
o Diet & Exercise Programs
o Cognitive Behavioral Therapy (CBT)
o Lifestyle and Patient Education
• Diagnostics & Digital Tools
o Blood Glucose and HbA1c Monitoring Devices
o Cognitive Screening Tools
o AI-Enabled Digital Therapeutics for Diabetes + Dementia Management
By Platform:
• Small Molecules (antidiabetics, cognitive enhancers)
• Biologics (GLP-1 analogs, monoclonals under research)
• Digital Health Solutions
By Technology:
• AI-Based Predictive Tools for Cognitive Decline in Diabetes
• Wearable Glucose + Cognitive Tracking Devices
• Biomarker-Based Diagnostics (insulin resistance markers, amyloid, tau)
By End Use:
• Hospitals & Memory Care Centers
• Diabetes Clinics with Integrated Cognitive Care
• Home Care Settings
• Research Institutes
By Application:
• Type 1 Diabetes with Dementia
• Type 2 Diabetes with Dementia
• Vascular Dementia Linked to Diabetes
• Alzheimer's Disease in Diabetic Patients
• Clinical Research
Segmentation Summary:
Pharmacological therapies dominate, but GLP-1 analogs, SGLT2 inhibitors, and AI-driven diagnostics are the fastest-growing segments. Integration of diabetes and dementia care is a key market shift.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71933/dementia-with-diabetes-market
Regional Analysis
North America
• ~42% share in 2024.
• High prevalence of diabetes and Alzheimer's disease.
• Strong adoption of GLP-1 therapies and digital health tools.
Europe
• ~30% share.
• Germany, UK, and France advancing integrated diabetes-dementia care.
• EMA approvals supporting innovation in GLP-1 and cognitive drug pipelines.
Asia-Pacific
• Fastest-growing region with CAGR of ~7.4%.
• Rising type 2 diabetes prevalence in China and India.
• Growing elderly populations in Japan and South Korea.
Middle East & Africa
• Smaller share but rising diabetes-driven dementia burden.
• Limited infrastructure but expanding awareness initiatives.
Latin America
• Brazil and Mexico leading growth.
• Expanding access to diabetes and dementia treatment centers.
Regional Summary:
North America and Europe dominate due to advanced healthcare infrastructure, while Asia-Pacific grows fastest due to rising diabetes prevalence and aging demographics.
Market Dynamics
Key Growth Drivers:
• Rising global prevalence of diabetes and dementia.
• Growing recognition of metabolic-cognitive links.
• Increasing adoption of GLP-1 therapies with cognitive benefits.
• AI-driven digital health and predictive monitoring.
Key Challenges:
• Lack of disease-modifying therapies for dementia.
• Complexity of managing multimorbid patients.
• High care costs and caregiver burden.
• Limited access in low-resource countries.
Latest Trends:
• Repurposing of antidiabetics (e.g., GLP-1 agonists) for dementia prevention.
• Digital twin and AI models predicting dementia risk in diabetic patients.
• Wearables integrating glucose monitoring with cognitive assessment.
• Lifestyle medicine programs targeting dual disease management.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71933
Competitor Analysis
Major Players in the Market:
• Eli Lilly and Company (GLP-1 agonists, Alzheimer's pipeline)
• Novo Nordisk A/S (Ozempic, semaglutide - GLP-1 therapies)
• Biogen Inc. (Alzheimer's biologics pipeline)
• Roche Holding AG (diagnostics & dementia research)
• Johnson & Johnson
• Novartis AG
• Pfizer Inc.
• Merck & Co., Inc. (diabetes portfolio)
• Abbott Laboratories (glucose monitoring devices)
• Dexcom, Inc. (continuous glucose monitoring systems with digital integration)
Competitive Summary:
Novo Nordisk and Eli Lilly dominate GLP-1 therapies, increasingly relevant for dementia care. Biogen and Roche drive dementia biologics, while Abbott and Dexcom lead integrated glucose monitoring. Competition focuses on metabolic-cognitive drug development, diagnostics, and digital health convergence.
Conclusion
The Dementia with Diabetes Market, valued at USD 8.4 billion in 2024, is projected to reach USD 15.2 billion by 2034, growing at a CAGR of 6.2%. Expanding recognition of the diabetes-dementia link, GLP-1 therapy adoption, and digital monitoring innovations will shape the market.
Key Takeaways:
• Dual disease burden is rising globally, especially in aging diabetic populations.
• North America and Europe dominate, while Asia-Pacific grows fastest.
• GLP-1 therapies and AI-driven diagnostics emerging as game-changers.
• Integrated, multimodal care models will define future treatment landscapes.
The next decade will transform dementia with diabetes care from fragmented management to integrated, precision-driven approaches, creating strong opportunities for pharma, medtech, and digital health innovators.
This report is also available in the following languages : Japanese (糖尿病を伴う認知症市場), Korean (당뇨병을 동반한 치매 시장), Chinese (糖尿病痴呆症市场), French (Marché de la démence et du diabète), German (Demenz mit Diabetes-Markt), and Italian (Mercato della demenza con diabete), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71933/dementia-with-diabetes-market#request-a-sample
Our More Reports:
Glaucoma Market
https://exactitudeconsultancy.com/reports/72285/glaucoma-market
Fuchs Endothelial Corneal Dystrophy (FECD) Market
https://exactitudeconsultancy.com/reports/72284/fuchs-endothelial-corneal-dystrophy-fecd-market
X-Linked Retinoschisis Market
https://exactitudeconsultancy.com/reports/72283/x-linked-retinoschisis-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dementia with Diabetes Market to Reach USD 15.2 Billion by 2034 here
News-ID: 4180930 • Views: …
More Releases from Exactitude Consultancy
Dyskinesia Market Emerging Trends and Growth Prospects 2034
Introduction
Dyskinesia, characterized by involuntary and uncontrolled movements, often arises as a side effect of long-term dopaminergic treatment in neurological disorders such as Parkinson's disease. As global cases of movement disorders continue to climb, so too does the need for therapies that effectively manage dyskinesia while preserving quality of life. The dyskinesia market has emerged as a critical segment of the wider central nervous system (CNS) therapeutics industry, shaped by aging…
Dup15q Syndrome market is expected to reach USD 240 million by 2034
Dup15q syndrome is a rare neurodevelopmental disorder caused by a duplication of chromosome region 15q11.2-q13.1. It is strongly associated with autism spectrum disorder (ASD), developmental delays, intellectual disability, hypotonia, and epilepsy, particularly infantile spasms and Lennox-Gastaut syndrome.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71935
The disorder has gained increasing recognition due to advances in genetic testing, growing awareness among clinicians, and active patient advocacy groups. While no disease-modifying therapies…
Drug-Induced Dyskinesia Market Detailed Industry Report Analysis 2025-2034
Introduction
Drug-induced dyskinesia (DID) is one of the most challenging side effects associated with long-term use of dopaminergic therapies, especially in Parkinson's disease management. Characterized by involuntary, erratic movements, DID significantly impacts quality of life and treatment adherence. Over the past decade, increasing awareness among physicians and patients, coupled with ongoing advancements in neuropharmacology, has placed the drug-induced dyskinesia market in the spotlight. With an aging population, rising prevalence of neurological…
Encephalitis Market is expected to reach USD 3.5 billion by 2034
Encephalitis Market Outlook 2024-2034: Expanding Diagnostics, Antiviral Therapies, and Global Awareness
Introduction
Encephalitis is an inflammation of the brain tissue caused by viral, bacterial, autoimmune, or idiopathic factors. It can lead to fever, seizures, confusion, memory loss, and long-term neurological complications. The condition is a serious medical emergency requiring immediate hospitalization and intensive care.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71937
The most common viral causes include Herpes Simplex Virus (HSV),…
More Releases for Diabetes
Major Force in the Diabetes Pen Market 2025: Diabetes Fuels Surge In Demand For …
How Will the Diabetes Pen Market Grow, and What Is the Projected Market Size?
The diabetes pen market is projected to grow from $29.24 billion in 2024 to $31.22 billion in 2025, at a CAGR of 6.8%. Growth is fueled by the rising need for managing diabetes, advancements in diabetes care, and an increasing focus on patient-friendly medication administration tools.
The diabetes pen market is projected to grow strongly, reaching $40.17 billion…
Diabetes Monitoring Devices Market: Regaining Its Glory| Ascensia Diabetes Care, …
The Latest Study Published by HTF MI Research on the "Diabetes Monitoring Devices Market'' evaluates market size, trend and forecast to 2029. The Diabetes Monitoring Devices market study includes significant research data and evidences to be a practical resource document for managers and analysts is, industry experts and other key people to have an easily accessible and self-analysed study to help understand market trends, growth drivers, opportunities and upcoming challenges…
Prevalence of Diabetes Drives Opportunities for Type-2 Diabetes Market
The Type-2 Diabetes Market Analysis, 2023, by MarkNtel Advisors, presents a well-researched, detail-driven, and accurate study for the stakeholders. This analysis entails prominent aspects like trends, & recent developments, drivers, opportunities, challenges, & restraints, among other parameters, influencing the overall industry expansion across different locations. This report comprises data from historic years (2018-21) & the base year (2022) to put together an estimation of the forecast period (2023-28).
According to Type-2 Diabetes Market…
Reverse Diabetes with Dr. Merritt’s Diabetes Reversal Recipe
[November 26, 2020] – People suffering from diabetes always search for ways to lower blood sugar levels in their bodies. Diabetes treatment available costs you hundreds of dollars yearly and also restricts you to a diabetic diet. That hampers your mental health and well-being. Apart from this, eye problems, kidney failure, amputations are some of the physical problems diabetic patients face.
Dr. Marlene Merritt (from the Merritt Wellness Center in…
Emerging trends for Diabetes Care Devices Market 2020 astonishing growth by Worl …
The global diabetes care devices market is expected to reach US$ 39,382.3 Mn in 2027 from US$ 23,354.3 Mn in 2018. The market is estimated to grow with a CAGR of 6.1% from 2020-2027.
Premium market insights recently published a report titled "Diabetes Care Devices Market Size and Forecast to 2026". The report includes an authentic and accurate research study into the global Diabetes Care Devices market based on a qualitative…
Diabetes Treatment
Diabetes Treatment is a important way to help manage the healthy ,easy to use and improve the way of the treatment of blood glucose monitoring system.
As living standards improve, an increasing obesity, the Diabetes Treatment has improved peoples living habits, disease control effect, is becoming more and more important.
The global Diabetes Treatment market is valued at 43700 million US$ in 2018 and will reach 58000 million US$ by the end…
